Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from ...

Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma.

Lipella Pharmaceuticals LIPO shares increased by 158.9% to $6.68 during Thursday's pre-market session. The market value of their outstanding shares is at $8.0 million. MBX Biosciences MBX stock moved ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on an acquisition, study results ...

CORAL GABLES, Fla. - Relmada Therapeutics , Inc. (NASDAQ:RLMD), a clinical-stage biotechnology firm with a market capitalization of $11.5 million, has announced the acquisition of Sepranolone, a Phase ...

Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed ...

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB Phase 2a results signaled improvement ...

Relmada Therapeutics, Inc. has recently received a notice from the Nasdaq Stock Market indicating that the company’s security did not maintain a minimum bid price of $1 per share for the 30 ...

Inc., a pharmaceutical company currently trading at $0.39 and showing a significant 89% decline over the past year according to InvestingPro data, has been alerted by the Nasdaq Stock Market of ...